Skip to main content
. 2012 Jul 19;2012:801495. doi: 10.1155/2012/801495

Figure 1.

Figure 1

Competing risks in multiple myeloma patients. Cumulative incidence of second primary cancers, disease progression, and death for patients randomized to either maintenance lenalidomide or placebo post HDT/SCT in the CALGB 100104 trial. In placebo treated patients (in blue), the risk of death and disease progression far exceeds the risk of SPM. Reprinted with permission [55].